Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis

Background: Risk of cancer is a major concern in the development of drugs for the treatment of obesity and diabetes. In randomized controlled trials (RCTs) of the liraglutide development program, a glucagon-like peptide-1 receptor agonist (GLP-1RA), subjects treated with the active drug had a higher...

Descripción completa

Detalles Bibliográficos
Autores principales: Piccoli, Giovana Fagundes, Mesquita, Leonardo A, Stein, Cinara, Aziz, Marina M, Zoldan, Maira, Degobi, Nathalia A H, Spiazzi, Bernardo Frison, Junior, Gilberto L Lopes, Colpani, Veronica, Gerchman, Fernando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Diabetes Mellitus and Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089886/
http://dx.doi.org/10.1210/jendso/bvab048.718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089886/
http://dx.doi.org/10.1210/jendso/bvab048.718

Ejemplares similares